Literature DB >> 8930004

Mood disorders in the general population represent an important and worldwide public health problem.

L L Judd1.   

Abstract

There are now credible empirical data to support the conclusions that depressive disorders are among the most common diseases that human beings experience, with approximately 11.3% of all adults afflicted by these disorders during any one year. In comparison to common medical illnesses, such as diabetes, hypertension, lung diseases, etc., depression is associated with significantly greater physical limitations, more dysfunction in ability to perform one's social and occupational role and with increased bed days and poorer estimation of personal health. The disability associated with depression is compounded and extended by the fact that depressive disorders have a high tendency toward recurrence, relapse and chronicity. Thus, not only are patients acutely disabled from acute episodes of major depression or dysthymia, but they tend to be disabled for significant segments of their lifetimes by the lifelong nature of the clinical course of the mood disorders. Further, the scientific evidence now available indicates that even subsyndromal symptomatic and minor depressions are associated with significant disability and dysfunction as well. Finally, the accumulation of high prevalence, the significant disability and the lifelong nature of depressive disorders results in a palpable impact on all of the national economies throughout the world. It can be confidently concluded that depressive disorders are among the most common, disabling and costly of any of the diseases in the health care spectrum and represent significant, serious public health problems.

Entities:  

Mesh:

Year:  1995        PMID: 8930004     DOI: 10.1097/00004850-199512004-00002

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  5 in total

Review 1.  Sertraline. A pharmacoeconomic evaluation of its use in depression.

Authors:  R Davis; M I Wilde
Journal:  Pharmacoeconomics       Date:  1996-10       Impact factor: 4.981

2.  Both acute and chronic buspirone treatments have different effects on regional 5-HT synthesis in Flinders Sensitive Line rats (a rat model of depression) than in control rats.

Authors:  Kyoko Nishi; Kazuya Kanemaru; Shu Hasegawa; Arata Watanabe; Mirko Diksic
Journal:  Neurochem Int       Date:  2008-11-25       Impact factor: 3.921

3.  The Symptom Structure of Postdisaster Major Depression: Convergence of Evidence from 11 Disaster Studies Using Consistent Methods.

Authors:  Carol S North; David Baron
Journal:  Behav Sci (Basel)       Date:  2021-01-13

4.  The impact of COVID-related perceived stress and social support on generalized anxiety and major depressive disorders: moderating effects of pre-pandemic mental disorders.

Authors:  Anna Monistrol-Mula; Mireia Felez-Nobrega; Joan Domènech-Abella; Philippe Mortier; Paula Cristóbal-Narváez; Gemma Vilagut; Beatriz Olaya; Montse Ferrer; Aina Gabarrell-Pascuet; Jordi Alonso; Josep Maria Haro
Journal:  Ann Gen Psychiatry       Date:  2022-02-14       Impact factor: 3.455

5.  Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial [ISRCTN45683816].

Authors:  Shahin Akhondzadeh; Hasan Fallah-Pour; Khosro Afkham; Amir-Hossein Jamshidi; Farahnaz Khalighi-Cigaroudi
Journal:  BMC Complement Altern Med       Date:  2004-09-02       Impact factor: 3.659

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.